Relationship of obesity and neurodegeneration: therapeutic potential of anorexigenic neuropeptides
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388963%3A_____%2F25%3A00639669" target="_blank" >RIV/61388963:_____/25:00639669 - isvavai.cz</a>
Result on the web
<a href="https://hdl.handle.net/11104/0370135" target="_blank" >https://hdl.handle.net/11104/0370135</a>
DOI - Digital Object Identifier
—
Alternative languages
Result language
angličtina
Original language name
Relationship of obesity and neurodegeneration: therapeutic potential of anorexigenic neuropeptides
Original language description
Recently discovered anorexigenic neuropeptides, such as prolactin-releasing peptide (PrRP) and cocaine- and amphetamine-regulated transcript (CART) peptide, represent new trends in development of anti-obesity and glucose-lowering, as well as neuroprotective compounds. Neuropeptides are released and acting directly in brain areas regulating food intake, but generally do not cross the blood-brain barrier if administered peripherally. We succeeded to design stable lipidized PrRP and CART peptide analogs with prolonged acute anorexigenic effect after peripheral administration in mice and rats. Repeated peripheral administration of the lipidized analogs resulted in long-lasting anti-obesity and antidiabetic effects in mouse models of diet induced obesity and insulin resistance. We showed that lipidization of anorexigenic peptides might be an effective way to increase stability and exert the effect to the central nervous system after peripheral administration in preclinical rodent models, for a potential treatment of obesity and related complications such as Type 2 diabetes and neurodegeneration.n
Czech name
—
Czech description
—
Classification
Type
O - Miscellaneous
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/LX22NPO5104" target="_blank" >LX22NPO5104: National Institute for Research of Metabolic and Cardiovascular Diseases</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů